Chronic cholestasis, defined as the impairment of bile acid formation and/or flow persisting for more than six months, encompasses a broad spectrum of hepatobiliary disorders, both heritable and ...
Rectify Pharmaceuticals Inc. has conducted preclinical testing on RTY-694, an oral dual-targeted positive functional modulator for use in the treatment of hepatobiliary disorders.
The central vein (CV) region, driven by the Wnt signaling pathway, and the portal vein (PV) region, driven by the Notch signaling pathway, enable us to construct a biomimetic liver lobule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results